NASDAQ:PCYC - Pharmacyclics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases. Receive PCYC News and Ratings via Email Sign-up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:PCYC Previous Symbol CUSIP71693310 WebN/A Phone+1-302-6587581 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 OptionableNot Optionable Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions What is Pharmacyclics' stock symbol? Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC." How were Pharmacyclics' earnings last quarter? Pharmacyclics, Inc. (NASDAQ:PCYC) released its quarterly earnings data on Friday, May, 1st. The biopharmaceutical company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to analysts' expectations of $226.27 million. View Pharmacyclics' Earnings History. Has Pharmacyclics been receiving favorable news coverage? Media headlines about PCYC stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pharmacyclics earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. How do I buy shares of Pharmacyclics? Shares of PCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact Pharmacyclics? Pharmacyclics' mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581. MarketBeat Community Rating for Pharmacyclics (NASDAQ PCYC)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 439 (Vote Outperform)Underperform Votes: 373 (Vote Underperform)Total Votes: 812MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe PCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCYC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/16/2018 by MarketBeat.com StaffFeatured Article: Hedge Funds - Risk or Reward?